Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth Contract SelectMDx with Roman Hospital - MDxHealth enters into commercial agreement for SelectMDx with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital in Rome - IDI.it / MDxHealth.com
MDxHealth Contract SelectMDx with Roman Hospital

 

PRZOOM - /newswire/ - Herstal, Belgium, 2018/02/28 - MDxHealth enters into commercial agreement for SelectMDx with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital in Rome - IDI.it / MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA, a world-leading player in the field of molecular diagnostic prostate cancer testing, today announces that it has entered into a commercial service agreement with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata (IDI), a leading research Hospital in Rome, to provide SelectMDx® for prostate cancer as a service test.

SelectMDx® is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. Under the terms of the agreement, the IDI Laboratory of Clinical Molecular Diagnostics, will perform SelectMDx testing locally by purchasing SelectMDx CE-marked IVD kits from MDxHealth, initially using the MDxHealth Central Lab in Nijmegen, The Netherlands for processing tests.

"We are excited that Istituto Dermopatico Immacolata Hospital is going to offer SelectMDx service testing to assist physicians in identifying patients at increased risk of harbouring aggressive, potentially lethal, prostate cancer" said Dr. Jan Groen, CEO of MDxHealth. "IDI's broad hospital network will significantly contribute to the successful market penetration of SelectMDx in Italy."

"We are delighted to offer this innovative test to our patients," commented Prof. Antonio M. Leozappa, President of Fondazione Luigi Maria Monti - IDI Hospital - Italy. "This partnership reinforces our commitment to provide our oncologists and urologists with a service test facilitating individualized and personalized medicine paths for patients. We believe that utilising state of the art diagnostics such as SelectMDx will allow our hospital to give our patients the best possible care."

About SelectMDx for Prostate Cancer
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs.

About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

About IDI
Since 1990 Istituto Dermopatico dell' Immacolata Hospital (idi.it) has been recognized by the Italian Ministry of Research and Health as a Research Hospital. The Hospital has several Research Departments looking after rare dermatological diseases, varying from inflammatory ones, to immune-mediated diseases to skin tumors, being the Reference Centre for whole Lazio Region. The Laboratory Diagnostic Department, following the Hospital strategies and clinical patient needs, as per the efficacy, efficiency and safety criteria, performs lab tests on different biological materials, for health promotion, prevention, diagnosis, prognosis, monitoring and therapeutic surveillance. The laboratory is composed by several units such as biochemistry, allergology, immunology, microbiology, pharmatoxicology, molecular biology and genetics.

Contacts
Dr. Andrea Barbieri - IDI
T: +39 06 66464564 / +39 06 6464454 - E: ufficio.stampa[.]idi.it.

Leon Melens - LifeSpring Life Sciences Communication
T: +31 6 538 16 427 - E: lmelens[.]lifespring.nl.

Amber Fennell / Chris Welsh / Hendrik Thys - Consilium Strategic Communications (IR & PR)
T: +44(0)20 3709 5701 - E: mdxhealth[.]consilium-comms.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth Contract SelectMDx with Roman Hospital

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
SelectMDx® | IDI
Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From MDxHealth, Inc. / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Cutting-Edge micro-CT Imaging Research Shines New Light on Mooted SARS-CoV-2 Treatments
Bruker Launches Revolutionary High-Speed AFM System for Single-Molecule Applications
Bruker Launches Second-Generation FluoroType® SARS-CoV-2 plus PCR Test for Detection of SARS-CoV-2 Viral Infections in Europe
SCHOTT Launches New VisiLED UV Ring Light for Stereo Microscopy
Citizen Care Pod Corp. Collaborates with WZMH Architects, PCL Construction, Insight Enterprises and Microsoft to Launch A Custom Mobile Testing Unit
American Regent Inc. Selects Sparta Systems’ TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network
Frost & Sullivan Analyzes the Future of Adhesion Prevention Products in the US and EU5
FORA Auto Temperature Measurement Station Provides Protection During COVID-19
TPEs Introduces A Range of TPE-compounds for Direct Contact with Blood and Body Fluid Applications in the Medical Sector
Safran and Segula Technologies Continue to Support the Fight Against Covid-19 by Adapting Decathlon’s Easybreath Subea Mask for Use in Hospitals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today